FY2025 EPS Estimates for Biohaven Lowered by Leerink Partnrs

Biohaven Ltd. (NYSE:BHVN) – Research analysts at Leerink Partnrs reduced their FY2025 EPS estimates for shares of Biohaven in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($6.90) per share for the year, down from their previous estimate of ($6.05). The consensus estimate for Biohaven’s current full-year earnings is ($8.85) per share. Leerink Partnrs also issued estimates for Biohaven’s FY2027 earnings at ($3.50) EPS and FY2028 earnings at ($1.65) EPS.

Biohaven (NYSE:BHVN) last released its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03).

BHVN has been the subject of several other research reports. TD Cowen increased their price target on Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $59.00 price objective on shares of Biohaven in a report on Tuesday, December 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 price objective (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. Finally, JPMorgan Chase & Co. raised their price target on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a report on Thursday, October 3rd. Thirteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $63.00.

Biohaven Price Performance

NYSE BHVN opened at $38.94 on Friday. Biohaven has a 12 month low of $26.80 and a 12 month high of $62.21. The business has a fifty day simple moving average of $39.80 and a 200 day simple moving average of $42.49.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs purchased 29,000 shares of Biohaven stock in a transaction that occurred on Monday, December 30th. The stock was bought at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the acquisition, the director now owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This trade represents a 1.24 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Biohaven

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Algert Global LLC grew its holdings in shares of Biohaven by 5.9% in the second quarter. Algert Global LLC now owns 7,402 shares of the company’s stock valued at $257,000 after purchasing an additional 412 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Biohaven by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock worth $4,206,000 after acquiring an additional 412 shares in the last quarter. KBC Group NV lifted its position in shares of Biohaven by 24.5% during the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after buying an additional 443 shares during the last quarter. Hsbc Holdings PLC boosted its stake in Biohaven by 6.1% in the second quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock valued at $286,000 after acquiring an additional 480 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in Biohaven by 19.1% during the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock worth $156,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.